Ras-mek-erk signaling regulates Nf1 heterozygous neointima formation

American Journal of Pathology

Volumn 184, Issue 1, 2014, Pages 79-85

  Stansfield, Brian K ^a   Bessler, Waylan K ^a   Mali, Raghuveer ^a   Mund, Julie A ^a   Downing, Brandon D ^a   Kapur, Reuben ^a   Ingram Jr , David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; CAROTID ARTERY INJURY; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ASSAY; ENZYME INHIBITION; GENE AMPLIFICATION; HETEROZYGOSITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CAROTID STENOSIS; DISEASE MODELS, ANIMAL; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NEOINTIMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84890414167     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.09.022     Document Type: Article

References (19)

1. T. Chang, K. Krisman, E.H. Theobald, J. Xu, J. Akutagawa, J.O. Lauchle, S. Kogan, B.S. Braun, and K. Shannon Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice J Clin Invest 123 2013 335 339
2. E.A. Lasater, F. Li, W.K. Bessler, M.L. Estes, S. Vemula, C.M. Hingtgen, M.C. Dinauer, R. Kapur, S.J. Conway, and D.A. Ingram Jr Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans J Clin Invest 120 2010 859 870
3. F. Li, A.M. Munchhof, H.A. White, L.E. Mead, T.R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F.C. Yang, and D.A. Ingram Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells Hum Mol Genet 15 2006 1921 1930
4. A.M. Munchhof, F. Li, H.A. White, L.E. Mead, T.R. Krier, A. Fenoglio, X. Li, J. Yuan, F.C. Yang, and D.A. Ingram Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells Hum Mol Genet 15 2006 1858 1869
5. J.M. Friedman, J. Arbiser, J.A. Epstein, D.H. Gutmann, S.J. Huot, A.E. Lin, B. McManus, and B.R. Korf Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force Genet Med 4 2002 105 111
6. E.A. Lasater, W.K. Bessler, L.E. Mead, W.E. Horn, D.W. Clapp, S.J. Conway, D.A. Ingram, and F. Li Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway Hum Mol Genet 17 2008 2336 2344
7. Y.Y. Zhang, T.A. Vik, J.W. Ryder, E.F. Srour, T. Jacks, K. Shannon, and D.W. Clapp Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines J Exp Med 187 1998 1893 1902
8. B.K. Stansfield, W.K. Bessler, R. Mali, J.A. Mund, B. Downing, F. Li, K.N. Sarchet, M.R. DiStasi, S.J. Conway, R. Kapur, and D.A. Ingram Jr. Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway Hum Mol Genet 22 2013 977 988
9. W.J. Jessen, S.J. Miller, E. Jousma, J. Wu, T.A. Rizvi, M.E. Brundage, D. Eaves, B. Widemann, M.O. Kim, E. Dombi, J. Sabo, A. Hardiman Dudley, M. Niwa-Kawakita, G.P. Page, M. Giovannini, B.J. Aronow, T.P. Cripe, and N. Ratner MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors J Clin Invest 123 2013 340 347
10. N. Lyubynska, M.F. Gorman, J.O. Lauchle, W.X. Hong, J.K. Akutagawa, K. Shannon, and B.S. Braun A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice Sci Transl Med 3 2011 76ra27
11. P.D. Boasberg, C.H. Redfern, G.A. Daniels, D. Bodkin, C.R. Garrett, and A.D. Ricart Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer Cancer Chemother Pharmacol 68 2011 547 552
12. E.B. Haura, A.D. Ricart, T.G. Larson, P.J. Stella, L. Bazhenova, V.A. Miller, R.B. Cohen, P.D. Eisenberg, P. Selaru, K.D. Wilner, and S.M. Gadgeel A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 16 2010 2450 2457
13. Y. Shiba, M. Takahashi, T. Yoshioka, N. Yajima, H. Morimoto, A. Izawa, H. Ise, K. Hatake, K. Motoyoshi, and U. Ikeda M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system Arterioscler Thromb Vasc Biol 27 2007 283 289
14. D.T. Le, N. Kong, Y. Zhu, J.O. Lauchle, A. Aiyigari, B.S. Braun, E. Wang, S.C. Kogan, M.M. Le Beau, L. Parada, and K.M. Shannon Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder Blood 103 2004 4243 4250
15. L.H. Dong, J.K. Wen, G. Liu, M.A. McNutt, S.B. Miao, R. Gao, B. Zheng, H. Zhang, and M. Han Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia Arterioscler Thromb Vasc Biol 30 2010 683 691
16. K.A. Rauen, L. Schoyer, F. McCormick, A.E. Lin, J.E. Allanson, and D.A. Stevenson Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: from bedside to bench and back Am J Med Genet Part A 152A 2010 4 24
17. G. Jin, J. Chieh-Hsi Wu, Y.S. Li, Y.L. Hu, J.Y. Shyy, and S. Chien Effects of active and negative mutants of Ras on rat arterial neointima formation J Surg Res 94 2000 124 132
18. A. Schober, A. Zernecke, E.A. Liehn, P. von Hundelshausen, S. Knarren, W.A. Kuziel, and C. Weber Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets Circ Res 95 2004 1125 1133
19. H.D. Danenberg, I. Fishbein, H. Epstein, J. Waltenberger, E. Moerman, J. Monkkonen, J. Gao, I. Gathi, R. Reichi, and G. Golomb Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery J Cardiovasc Pharmacol 42 2003 671 679